Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Trading Update

4 Nov 2014 07:00

RNS Number : 0309W
Biome Technologies PLC
04 November 2014
 



04 November 2014

 

 

Biome Technologies plc ("Biome", "the Company" or "the Group")

Trading Update

 

 

Biome Technologies plc, a leading bioplastics and radio frequency technology business, today publishes a trading update for the nine months ended 30 September 2014.

 

Total Group revenues achieved for the third quarter were £0.5m (Q3 2013: £0.6m) taking Group revenues for the nine months to 30 September 2014 to £2.8m, 85% ahead of the same period in 2013 (2013: £1.5m). The Group's cash position as at 30 September 2014 was £2.8m (30 June 2014: £3.1m).

Bioplastics Division

Revenues for the Bioplastics division in Q3 were £0.1m (Q3 2013: £0.4m), down substantially on the previous two quarters. Offtake reduced to the single-serve coffee market in the USA as the main customer responded to technical challenges in the market place and ran down stocks ahead of re-launches. The Board believes that these effects are temporary and that revenue growth will resume in the near future.

Further progress was made in the development of the pipeline of new bioplastic polymers with technical and customer trials continuing in both the food service and paper-board coating sectors. The business launched a new product in September, formulated to improve both speed and performance in 3D printing applications, whilst retaining impeccable environmental credentials. This is the division's first foray into this emerging sector and initial response from end-use customers is encouraging.

Earlier in the year, the division announced the successful completion of a feasibility study undertaken in conjunction with the University of Warwick and supported by Innovate UK (formerly the Technology Strategy Board). This study examined the feasibility of producing a bacterially derived lignin-based alternative to the oil-based chemicals used in the manufacture of bioplastics. The Board is exploring options for further scale-up of this technology and is awaiting the result of a further grant application to Innovate UK. The result of this application is expected in the near future.

 

Stanelco RF Technologies Division

Revenues for the RF division remained firm at £0.4m (Q3 2013: £0.2m). Demand from the optical fibre furnace market in Asia continues to underpin revenues whilst products for a broader portfolio of market applications are progressing well. The unit's order-book into 2015 is robust and recruitment has been recently completed to extend both capacity and capability.

 

Outlook

The Board remains confident of meeting market expectations for the year.

 

-Ends-

 

For further information please contact:

 

Biome Technologies plc

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

Daniel Stewart & Company plc

Paul Shackleton (Nominated Adviser)

Mark Treharne (Broker)

www.danielstewart.co.uk

Tel: +44 (0) 20 7776 6550

Allenby Capital

Chris Crawford/Kelly Gardiner

www.allenbycapital.com

Tel: +44 (0) 20 3002 2070

FTI Consulting

Oliver Winters

www.fticonsulting.com

Tel: +44 (0) 20 3727 1535

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTQKNDBABDDPDK
Date   Source Headline
15th May 20067:01 amRNSAppointment of Adviser
3rd May 20061:05 pmRNSNotifiable Interest
2nd May 20064:58 pmRNSResult of AGM
2nd May 20062:00 pmRNSAGM Statement
10th Apr 20063:12 pmRNSAnnual Report and Accounts
7th Apr 20062:46 pmRNSAdditional Listing
13th Mar 20067:02 amRNSDirectorate Change
28th Feb 20067:02 amRNSPreliminary Results
24th Feb 20067:02 amRNSCooperation with Wal-Mart
14th Feb 20069:07 amRNSAdditional Listing
14th Feb 20067:00 amRNSUS FDA approval for Starpol
9th Feb 200610:42 amRNSIsraCaps new licence terms
9th Feb 20067:02 amRNSRe: BioProgress plc
16th Dec 20057:01 amRNSFunding for R&D facility
16th Dec 20057:01 amRNSPre Close Update
14th Dec 20057:01 amRNSLandmark deal with Perseco
8th Dec 200510:25 amRNSShare Listing Application
30th Nov 20055:40 pmRNSDirectorate Change
28th Nov 20059:24 amRNSBoard Changes
8th Nov 20057:01 amRNSPatent sale process update
3rd Nov 20054:47 pmRNSExercise of Options
1st Nov 20057:02 amRNSChange of Adviser
12th Oct 20057:00 amRNSApproval of Starpol
3rd Oct 20057:00 amRNSPatent Disposal & Update
22nd Sep 20057:02 amRNSRe Agreement
12th Sep 20057:03 amRNSDevelopment of capsule
5th Sep 20057:03 amRNSRe: Completion
30th Aug 20053:30 pmRNSDoc re. Result of EGM
30th Aug 200511:08 amRNSEGM Statement
30th Aug 20057:03 amRNSRe Agreement
5th Aug 200511:15 amRNSRe posting of circular
1st Aug 20057:01 amRNSDirector Appointment
28th Jul 20057:01 amRNSUpdate re: trials with ASDA
26th Jul 20057:00 amRNSContract Win
19th Jul 20057:00 amRNSRe Agreement
5th Jul 20057:01 amRNSRe Joint Venture
29th Jun 20057:00 amRNSInterim Results
22nd Jun 20057:00 amRNSUpdate re trials with Asda
8th Jun 20055:29 pmRNSAdditional Listing
8th Jun 200510:00 amRNSAppointment of Group MD
8th Jun 20057:50 amRNSPlacing of Ordinary Shares
6th Jun 20057:01 amRNSAcquisition
3rd Jun 20053:02 pmRNSIssue of Equity
23rd May 20057:01 amRNSRe Contract
17th May 200512:12 pmRNSAdditional Listing
10th May 20057:00 amRNSUpdate re. trials with Asda
29th Apr 20053:46 pmRNSHolding(s) in Company
25th Apr 20053:27 pmRNSDirector Shareholding
22nd Apr 20052:24 pmRNSResult of AGM
22nd Apr 200511:31 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.